Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026)
Viking Therapeutics' (VKTX) quarterly Income from Continuing Operations came in at -$128.1 million in Q2 2026, down 95.38% year-over-year from -$2.8 billion in Q2 2025, and up 19.12% quarter-over-quarter from -$158.3 million in Q1 2026.
Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Viking Therapeutics has disclosed Income from Continuing Operations across 13 years of filings, most recently posting -$128.1 million for Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 95.38% year-over-year to -$128.1 million; the TTM figure through Jun 2026 stood at -$534.9 million (down 211.76% YoY), while the FY2025 annual figure was -$359.6 million, down 227.0% from the prior year.
- Income from Continuing Operations came in at -$128.1 million for Q2 2026 at Viking Therapeutics, up from -$158.3 million in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of -$15.7 million in Q3 2022 to a low of -$158.3 million in Q1 2026.
- Average Income from Continuing Operations over 5 years is -$50.6 million, with a median of -$24.8 million recorded in 2023.
- Year-over-year, Income from Continuing Operations fell 10.44% in 2023 and slumped 345.56% in 2025.
- Over 5 years, Income from Continuing Operations stood at -$19.6 million in 2022, then fell by 25.72% to -$24.6 million in 2023, then tumbled by 44.0% to -$35.4 million in 2024, then sank by 345.56% to -$157.7 million in 2025, then grew by 18.8% to -$128.1 million in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were -$128.1 million in Q2 2026, -$158.3 million in Q1 2026, and -$157.7 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Viking Therapeutics | 4.86 Bn | 4.86 Bn | - | -128.05 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -128.05 Mn |
| Mar 31, 2026 | -158.33 Mn |
| Dec 31, 2025 | -157.70 Mn |
| Sep 30, 2025 | -90.79 Mn |
| Jun 30, 2025 | -65.54 Mn |
| Mar 31, 2025 | -45.61 Mn |
| Dec 31, 2024 | -35.39 Mn |
| Sep 30, 2024 | -25.03 Mn |
| Jun 30, 2024 | -22.23 Mn |
| Mar 31, 2024 | -27.33 Mn |
| Dec 31, 2023 | -24.58 Mn |
| Sep 30, 2023 | -22.53 Mn |
| Jun 30, 2023 | -19.19 Mn |
| Mar 31, 2023 | -19.50 Mn |
| Dec 31, 2022 | -19.55 Mn |
| Sep 30, 2022 | -15.75 Mn |
| Jun 30, 2022 | -17.38 Mn |
| Mar 31, 2022 | -17.14 Mn |
| Dec 31, 2021 | -12.35 Mn |
| Sep 30, 2021 | -13.28 Mn |
Viking Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=VKTX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "VKTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=VKTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();